Skip to main content
Hematology and Oncology
ALL Specialities
ALL Specialities
/
Hematology and Oncology
Blood & Cancer Podcast
CME
Diseases & Conditions
Nonmalignant Hematologic Disorders
Anemia
Bleeding Disorders
Thrombosis
Breast Cancer
CNS/Brain Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Renal Cell Carcinoma
Gynecologic Cancer
Head & Neck/Thyroid Cancers
Leukemia, Myelodysplasia, Transplantation
ALL
AML
Cellular Therapy
CLL
CML
Myelodysplastic Syndrome
Transplantation
Lung Cancer
Lymphoma & Plasma Cell Disorders
B Cell Lymphoma
Follicular Lymphoma
Hodgkin Lymphoma
Mantle Cell Lymphoma
Multiple Myeloma
Non-Hodgkin Lymphoma
T Cell Lymphomas
Melanoma
Nonmelanoma Skin Cancer
Sarcoma and GIST
COVID-19 Updates
Conference Coverage
News
Study results differ on benefits of proton radiotherapy in NSCLC
Publish date:
June 16, 2016
AT THE 2016 ASCO ANNUAL MEETING
References
jcraig@frontlinemedcom.com
On Twitter
@jessnicolecraig
Pages
« first
1
2
Recommended Reading
Investigational CDK4/6 inhibitor shows activity, less toxicity
MDedge Hematology and Oncology
VIDEO: Dr. Roy Herbst talks combinations, evolutions, and innovations in lung cancer
MDedge Hematology and Oncology
Liquid biopsies prove useful alternative to tissue biopsies
MDedge Hematology and Oncology
MyPathway: Targeted therapies show promise in nonindicated tumors
MDedge Hematology and Oncology
Novel antibody drug conjugate shows promise in SCLC
MDedge Hematology and Oncology
Vandetanib shows variable response, toxicity in RET-positive NSCLC
MDedge Hematology and Oncology
Web app boosts lung cancer survival
MDedge Hematology and Oncology
Dual checkpoint blockade doubles response in SCLC
MDedge Hematology and Oncology
Immune agonist, checkpoint inhibitor combo shows good tolerability
MDedge Hematology and Oncology
Pembrolizumab paired with immunostimulator is safe and tolerable
MDedge Hematology and Oncology
Lung Cancer
All Specialties
